Literature DB >> 27142681

Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Byung Sup Kim1, Ho Jun Seol2, Jung-Il Lee3, Hyung Jin Shin3, Kwan Park3, Doo-Sik Kong3, Do-Hyun Nam3, Yang-Sun Cho4.   

Abstract

To discuss the appropriate treatment strategy for NF2-related vestibular schwannoma (VS) according to our experiences, we analyzed long-term clinical and radiological data focusing on NF2-related VS patients. Seventeen NF2-related VS patients were included. Based on their first management modality for VS, we classified these patients into the following four groups: microsurgery (MS), fractionated gamma knife radiosurgery (f-GKS), single session gamma knife radiosurgery (s-GKS), and conservative management (CM). Each patient was assessed for each separate ear. Changes of tumor volume and hearing status for 32 ears in 17 patients according to their first treatment modality were evaluated. The mean follow-up duration and tumor volume of the MS (4 ears, 4 patients), f-GKS (12 ears, 10 patients), s-GKS (8 ears, 7 patients), and CM (8 ears, 7 patients) groups were 3.9 years and 1.6 mL; 5.1 years and 11.1 mL; 8.4 years and 5.6 mL; and 6.1 years and 1.6 mL, respectively. Relatively lower local control rates were observed in the MS and the CM group (0 and 12.5 %, respectively). On the other hand, better local control rates for follow-up periods of 5.1 and 8.4 years were achieved in the f-GKS and the s-GKS groups (75 and 50 %, respectively). However, hearing preservation in all treatment modalities could not be achieved effectively. Long-term preservation of hearing in at least one serviceable ear as well as tumor control should be considered for each patient. Therefore, a proper treatment option should be selected at the appropriate time according to clinical characteristics of individual patients.

Entities:  

Keywords:  Gamma knife; Hearing; Microsurgery; Neurofibromatosis type 2; Vestibular schwannoma

Mesh:

Year:  2016        PMID: 27142681     DOI: 10.1007/s10143-016-0728-5

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  37 in total

1.  Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution.

Authors:  Stephanie E Combs; Sigrid Volk; Daniela Schulz-Ertner; Peter E Huber; Christoph Thilmann; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Management strategy of vestibular schwannoma in neurofibromatosis type 2.

Authors:  Haitham Ahmad Odat; Enrico Piccirillo; Giuliano Sequino; Abdelkader Taibah; Mario Sanna
Journal:  Otol Neurotol       Date:  2011-09       Impact factor: 2.311

4.  Early proactive management of vestibular schwannomas in neurofibromatosis type 2.

Authors:  D E Brackmann; J N Fayad; W H Slattery; R A Friedman; J D Day; W E Hitselberger; R M Owens
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

5.  Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2.

Authors:  M Samii; C Matthies; M Tatagiba
Journal:  Neurosurgery       Date:  1997-04       Impact factor: 4.654

6.  [Neurofibromatosis type 2. Preliminary results of gamma knife radiosurgery of vestibular schwannomas].

Authors:  P H Roche; J Régis; W Pellet; J M Thomassin; R Grégoire; H Dufour; J C Peragut
Journal:  Neurochirurgie       Date:  2000-09       Impact factor: 1.553

7.  Type 2 neurofibromatosis: the need for supraregional care?

Authors:  D G Evans; R Ramsden; S M Huson; R Harris; R Lye; T T King
Journal:  J Laryngol Otol       Date:  1993-05       Impact factor: 1.469

8.  Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients.

Authors:  William H Slattery; Laurel M Fisher; William Hitselberger; Rick A Friedman; Derald E Brackmann
Journal:  J Neurosurg       Date:  2007-04       Impact factor: 5.115

9.  Conservative management of vestibular schwannomas: an effective strategy.

Authors:  Gian Gaetano Ferri; Giovanni Carlo Modugno; Antonio Pirodda; Antonio Fioravanti; Fabio Calbucci; Alberto Rinaldi Ceroni
Journal:  Laryngoscope       Date:  2008-06       Impact factor: 3.325

10.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08
View more
  5 in total

1.  Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.

Authors:  Marisa A Fuse; Christine T Dinh; Jeremie Vitte; Joanna Kirkpatrick; Thomas Mindos; Stephani Klingeman Plati; Juan I Young; Jie Huang; Annemarie Carlstedt; Maria Clara Franco; Konstantin Brnjos; Jackson Nagamoto; Alejandra M Petrilli; Alicja J Copik; Julia N Soulakova; Olena Bracho; Denise Yan; Rahul Mittal; Rulong Shen; Fred F Telischi; Helen Morrison; Marco Giovannini; Xue-Zhong Liu; Long-Sheng Chang; Cristina Fernandez-Valle
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

2.  A Xenograft Model of Vestibular Schwannoma and Hearing Loss.

Authors:  Christine T Dinh; Olena Bracho; Christine Mei; Esperanza Bas; Cristina Fernandez-Valle; Fred Telischi; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

3.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

4.  Microsurgery for patients diagnosed with neurofibromatosis type 2 complicated by vestibular schwannomas: Clinical experience and strategy for treatments.

Authors:  Li-Hua Chen; Hong-Tian Zhang; Ru-Xiang Xu; Li Zhang; Wen-De Li; Kai Sun
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

5.  Vestibular schwannoma associated with neurofibromatosis type 2: Clinical course following stereotactic radiosurgery.

Authors:  Junhyung Kim; Yukyeng Byeon; Sang Woo Song; Young Hyun Cho; Chang-Ki Hong; Seok Ho Hong; Jeong Hoon Kim; Do Heui Lee; Ji Eun Park; Ho Sung Kim; Young-Hoon Kim
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.